Cambrex, a global pharmaceutical company based in East Rutherford, announced Tuesday the start of a $30 million research and development facility at its Milan, Italy site.
The facility will add advanced analytical development and process R&D capabilities, alongside upgrades to multiple production plants, reinforcing Cambrex’s commitment to supporting the pharmaceutical industry’s most complex small molecule development.
The Milan R&D expansion is expected to be completed in the second half of 2027. To accommodate future growth and rising demand for CDMO services, Cambrex has also acquired additional land adjacent to the site, ensuring the capacity to expand and innovate for years to come.
The Cambrex Profarmico Milano site, which marks its 80th anniversary this year, has a distinguished legacy of supporting pharmaceutical development and manufacturing for its global client base, the company said in a release.
The Milan team recently gathered to celebrate this milestone, reflecting on eight decades of scientific achievement and dedication to advancing human health.
Cambrex Chief Operating Officer Claudio Russolo said breaking ground on this new facility is a testament to the enduring legacy and expertise of the team in Milan.
“For 80 years, this site has been a cornerstone of pharmaceutical manufacturing in Europe,” he said. “With this expansion, we are investing not only in new technologies and capabilities, but in the future of our people and our partners.”
The investment builds on Cambrex’s legacy of scientific expertise and manufacturing excellence while positioning the company for its next chapter of growth. By expanding R&D capabilities in Milan, Cambrex is strengthening its ability to address the increasing complexity of today’s small molecule therapies.
Cambrex is a leading global contract development and manufacturing organization (CDMO) that provides drug substance development and manufacturing across the entire drug lifecycle, as well as comprehensive analytical services.
Cambrex is owned by the London-based private equity firm Permira, which acquired the company in December 2019 for approximately $2.4 billion, taking the previously public corporation private.
The news comes a day after New Jersey-based global pharma company Bristol Myers Squibb announced it was building a $2.3 billion manufacturing facility in Texas.
